3+ hour, 33+ min ago  (677+ words) Intelligent Bio Solutions has initiated a validation study to cut the analysis time of its Intelligent Fingerprinting Drug Screening System from roughly 10 minutes to under three minutes, with sample collection already completed in under a minute. The program targets a…...

11+ mon, 1+ day ago  (358+ words) CRISPR Therapeutics and Sirius Therapeutics have partnered to develop and commercialize SRSD107, a long-acting si RNA therapy for thromboembolic disorders. SRSD107 targets Factor XI, a key driver of thrombosis, and has shown promising results in Phase 1 trials with sustained efficacy up to…...

3+ hour, 34+ min ago  (651+ words) In a retrospective cohort of 28 heavily pretreated metastatic triple-negative breast cancer patients, leronlimab exposure was associated with induction of PD-L1 on circulating tumor and macrophage-like cells, and 17. 9% (5/28) of patients remained alive beyond 60 months. Higher leronlimab dose and use in combination…...

4+ hour, 22+ min ago  (645+ words) In early Phase 1 dose escalation, BBOT's pan-KRAS inhibitor BBO-11818 produced a confirmed partial response in pancreatic ductal adenocarcinoma and showed dose-related tumor shrinkage across KRAS'mutant solid tumors with a generally manageable safety profile. Updated Phase 1 data are slated for the…...

3+ hour, 34+ min ago  (669+ words) ORR signals dominated Junshi Biosciences" AACR update: in first'line metastatic colorectal cancer, JS207 plus XELOX produced a 71. 0% objective response rate and 96. 8% disease control among 31 evaluable patients; in first'line advanced hepatocellular carcinoma, JS207 plus JS007 achieved a 45. 5% ORR and 86. 4% disease control across 22 evaluable patients....

3+ hour, 34+ min ago  (596+ words) The Clinical Trial Vanguard Genetic Data Offers Breakthrough Hope for Pancreatic Cancer ct DNA from 123 atebimetinib-treated patients showed rare emergent MAPK pathway alterations and minimal early molecular evolution, with resistance patterns dispersing outside the MAPK axis. The dataset spans 86 patients…...

4+ hour, 22+ min ago  (684+ words) An independent data monitoring review of Parts A and B of Atsena Therapeutics" LIGHTHOUSE study found ATSN-201 safe and showing preliminary efficacy signals, including a majority of treated patients with foveal schisis closure and improvements on microperimetry, best-corrected visual acuity,…...

4+ hour, 20+ min ago  (648+ words) Orion Pharma has secured US FDA Orphan Drug Designation for ODM-212 in mesothelioma, adding regulatory leverage to a first-in-class program that is already in a global Phase 2 trial evaluating malignant pleural mesothelioma (MPM), epithelioid hemangioendothelioma (EHE), and other Hippo-pathway'dysregulated solid…...

20+ hour, 17+ min ago  (458+ words) Mind Med is using a custom large language model to audit clinician-rated assessments across all three of its phase three LSD trials. Dan Karlin, Chief Medical Officer at Mind Med, presented the approach as a case study at the Panagora…...

19+ hour, 49+ min ago  (387+ words) Critically, the Medable CEO argued that China's speed advantage in clinical development is not technology-driven. Chinese sponsors are winning on process fundamentals " patient enrollment, site engagement, and operational execution " often while still transitioning from paper to digital systems. That distinction…...